IVBXF
Price:
$4.5682
Market Cap:
$7.47B
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarci...[Read more]
Industry
Biotechnology
IPO Date
2019-09-04
Stock Exchange
PNK
Ticker
IVBXF
According to Innovent Biologics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -41.53. This represents a change of -82.25% compared to the average of -234.03 of the last 4 quarters.
The mean historical PE Ratio of Innovent Biologics, Inc. over the last ten years is -36.13. The current -41.53 PE Ratio has changed 11.39% with respect to the historical average. Over the past ten years (40 quarters), IVBXF's PE Ratio was at its highest in in the March 2017 quarter at 0. The PE Ratio was at its lowest in in the March 2023 quarter at -1241.07.
Average
-36.13
Median
-30.51
Minimum
-90.90
Maximum
-1.26
Discovering the peaks and valleys of Innovent Biologics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.19%
Maximum Annual PE Ratio = -1.26
Minimum Annual Increase = -96.92%
Minimum Annual PE Ratio = -90.90
Year | PE Ratio | Change |
---|---|---|
2023 | -52.98 | 162.17% |
2022 | -20.21 | 11.52% |
2021 | -18.12 | -80.07% |
2020 | -90.90 | 460.88% |
2019 | -16.21 | 1.19% |
2018 | -1.26 | -96.92% |
2017 | -40.81 | -15.97% |
The current PE Ratio of Innovent Biologics, Inc. (IVBXF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-30.44
5-year avg
-39.68
10-year avg
-36.13
Innovent Biologics, Inc.’s PE Ratio is less than Telix Pharmaceuticals Limited (119.46), less than Keros Therapeutics, Inc. (-13.01), less than MAIA Biotechnology, Inc. (-2.30), less than Graphite Bio, Inc. (-0.13), less than Genscript Biotech Corporation (0), less than Oxford Nanopore Technologies plc (-18.26), less than Nuvalent, Inc. (-4.44), less than Crinetics Pharmaceuticals, Inc. (-33.15), less than Inhibrx Biosciences, Inc. (-17.44), less than Merus N.V. (0.14), less than Lyell Immunopharma, Inc. (-14.44), less than Kronos Bio, Inc. (-1.52), less than Theseus Pharmaceuticals, Inc. (-0.54), less than Cullinan Oncology, Inc. (-3.19), less than Mersana Therapeutics, Inc. (-6.18), less than Relay Therapeutics, Inc. (-2.17), less than Arcus Biosciences, Inc. (-2.43), less than null (-5.70),
Company | PE Ratio | Market cap |
---|---|---|
119.46 | $4.48B | |
-13.01 | $2.27B | |
-2.30 | $69.68M | |
-0.13 | $185.19M | |
0 | $3.22B | |
-18.26 | $1.70B | |
-4.44 | $6.22B | |
-33.15 | $5.14B | |
-17.44 | $223.08M | |
0.14 | $3.54B | |
-14.44 | $321.28M | |
-1.52 | $55.49M | |
-0.54 | $181.50M | |
-3.19 | $925.89M | |
-6.18 | $229.40M | |
-2.17 | $959.33M | |
-2.43 | $1.42B | |
-5.70 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innovent Biologics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Innovent Biologics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Innovent Biologics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Innovent Biologics, Inc. (IVBXF)?
What is the highest PE Ratio for Innovent Biologics, Inc. (IVBXF)?
What is the 3-year average PE Ratio for Innovent Biologics, Inc. (IVBXF)?
What is the 5-year average PE Ratio for Innovent Biologics, Inc. (IVBXF)?
How does the current PE Ratio for Innovent Biologics, Inc. (IVBXF) compare to its historical average?